Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Biomed Rep ; 3(2): 167-172, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25798242

ABSTRACT

Establishing a transcriptomic profile of human hepatocellular liver cancer (HCC) progression is a complex undertaking. A rat model of HCC was employed to develop a transcriptomic profile. Using three interventions, preneoplastic lesions appeared after 30 days and they progressed to HCC by 9 months. Preneoplastic and cancer lesions were characterized for transcriptomic analysis, and RNA from total liver homogenates was obtained at 1, 7, 11 and 16 days after the initiation treatment. RNA from dissected persistent preneoplastic lesions, adjacent tissue or cancer tissue was used for 30 days, and 5, 9, 12 and 18 months. The GeneChip® Rat Exon 1.0 ST arrays, Partek software and an Affymetrix console were employed for these analyses. LGALS3BP was differentially expressed at each time point, from the initial period, through the preneoplastic evolution period and until the end of cancer progression period. Twelve differentially expressed genes common to the preneoplastic evolution and to the cancer progression period were detected, which included ABCC3. Validation of the microarrays was confirmed by reverse transcription-quantitative polymerase chain reaction of six genes, including LGALS3BP and ABCC3. Of note, the proteins of these two genes are associated with the multidrug response complex, and evasion of immune surveillance and negative regulation of T cell proliferation. This model is useful for identifying candidate genes, and to validate them with regards to determining their relevance in rat HCC progression.

2.
Anticancer Drugs ; 24(4): 394-405, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23388162

ABSTRACT

We present a study of the chemoprotective effects of two caffeic acid phenethyl ester (CAPE)-related structures: LQM717 and LQM706. The modified resistant hepatocyte model in rats was used to study the chemoprevention of these CAPE analogues, which are inexpensive and easily obtained. In the liver cancer model used, we detected extensive necrosis and lipid peroxidation after 24 h, many altered hepatic foci, putatively preneoplastic lesions with γ-glutamyl transpeptidase staining after 30 days, and liver tumors at 12 months. We tested the effect of the CAPE analogues on necrosis, lipid peroxidation, proliferation, p65 activation, altered hepatic foci, and tumors. Both compounds exerted protective effects on lipid peroxidation, necrosis, cell proliferation, p65 activation, and preneoplastic lesions. Rats under a carcinogenic protocol showed a 52, 71.74, and 51.6% decrease in the number of preneoplastic nodules when pretreated with CAPE, LQM706, and LQM717, respectively. At 12 months after carcinogenic treatment, eight of eight rats developed liver cancer, whereas in the group of rats that received pretreatment with CAPE, LQM706, or LQM717, 62.5, 83.3, or 42.85%, respectively, had tumors. In conclusion, LQM717 has the potential to enhance chemoprotection activity much better than CAPE by markedly reducing the formation of liver cancers in this model, and this is a compound that is easy to obtain.


Subject(s)
Acetanilides/pharmacology , Anticarcinogenic Agents/therapeutic use , Antioxidants/therapeutic use , Caffeic Acids/therapeutic use , Cinnamates/therapeutic use , Hepatocytes/drug effects , Liver Neoplasms, Experimental/drug therapy , Phenylethyl Alcohol/analogs & derivatives , Precancerous Conditions/drug therapy , 2-Acetylaminofluorene , Acetanilides/chemical synthesis , Acetanilides/therapeutic use , Animals , Anticarcinogenic Agents/chemical synthesis , Anticarcinogenic Agents/pharmacology , Antioxidants/chemical synthesis , Antioxidants/pharmacology , Caffeic Acids/pharmacology , Carcinogens , Cell Division/drug effects , Cinnamates/chemical synthesis , Cinnamates/pharmacology , Diethylnitrosamine , Drug Evaluation, Preclinical , Drug Resistance , Glutathione S-Transferase pi/analysis , Hepatectomy/adverse effects , Hepatocytes/chemistry , Hepatocytes/pathology , Ki-67 Antigen/analysis , Lipid Peroxidation/drug effects , Liver Neoplasms, Experimental/chemically induced , Liver Neoplasms, Experimental/pathology , Male , Molecular Structure , Phenylethyl Alcohol/pharmacology , Phenylethyl Alcohol/therapeutic use , Precancerous Conditions/chemically induced , Precancerous Conditions/pathology , Rats , Rats, Inbred F344 , Transcription Factor RelA/antagonists & inhibitors , Transcription Factor RelA/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...